Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 26, 2020

UCT and partners develop and validate new TB blood test

Researchers from the University of Cape Town’s (UCT) South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research – Seattle, US, and a consortium of collaborators have developed and validated a new test for tuberculosis (TB).

Researchers from the University of Cape Town’s (UCT) South African Tuberculosis Vaccine Initiative (SATVI), the Center for Global Infectious Disease Research – Seattle, US, and a consortium of collaborators have developed and validated a new test for tuberculosis (TB).

Named RISK6, the new blood-based test can identify healthy individuals who are at risk of developing TB. It can also identify people with subclinical or clinical disease and help understand how well a patient would respond to the treatment.

The test, which can be applied to capillary blood collected by finger prick, is currently validated in seven cohorts across two continents.

Furthermore, RISK6 could be developed into a rapid, finger prick blood-based test device that can be used at points of care.

SATVI immunology deputy director Thomas Scriba said: “Finding everyone with TB so that they can receive antibiotic treatment to get better and so that they do not infect others is critically important.

“Most people with TB are identified too late when they have already passed the bacterium to family and friends.”

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

According to the World Health Organization (WHO) Global TB Report 2019, more than 1.7 billion people are infected with the bacterium Mycobacterium tuberculosis worldwide. Among them, over ten million people developed TB, while 1.4 million died in 2018.

The existing diagnostic tools for TB can be administered only in people with advanced TB and who can produce sputum samples. Currently, there are no effective tests that identify the disease in people who are not symptomatic.

In the study, researchers also found that RISK6 has the ability to detect subclinical and clinical disease in people with and without HIV.

The team is currently working to develop a hand-held device that can perform the test immediately after blood is collected by finger prick.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU